Proactive Investors' editor Ian Lyall reports on the release this afternoon by Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT) of encouraging data for its treatment for Duchenne Muscular Dystrophy (DMD).
The interim results for the PhaseOut study revealed a "statistically significant and meaningful" reduction in muscle damage in patients taking the company's treatment, ezutromid.
Duchenne Muscular Dystrophy is a rare muscle-wasting disease that affects boys.
Meet Reward Minerals Ltd, Recce Ltd, Rimfire Pacific Mining NL and Aus Tin Mining at our event, Melbourne, 31 January 2018.Register here >>